

## REMARKS

Claims 3-10 are pending. An Appendix of Pending Claims is attached for the Examiner's convenience.

Applicants note that pending claims 11-12 were not included in either Invention I or II. Applicants have not canceled these claims as they wish to be entitled to the consideration of claims 11-12 if a generic claim is allowed.

Attached hereto is a marked-up version of the changes made to the claims by the "Restriction and Amendment". The attached page is captioned **"Version with markings to show changes made."**


The Commissioner is authorized to charge any additional fees, including any extension fees, which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-68752-1/RFT/RMS).

Respectfully submitted,

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP

Dated: April 9, 2001

Four Embarcadero Center - Suite 3400  
San Francisco, California 94111-4187  
Telephone: (415) 781-1989  
1048425.RMK

By:   
Renee M. Kosslak, Reg. No. 47,717 for  
Richard F. Trecartin, Reg. No. 31,801

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Claim 1 has been canceled.

Claim 2 has been canceled.

## APPENDIX OF PENDING CLAIMS

3. Embryonic metanephric tissue which has been pretreated with a growth factor composition comprising at least one growth factor for metanephric development wherein said pretreated metanephric tissue has enhanced renal development or function in recipients as compared to metanephric tissue which has not been pretreated with said growth factor composition.
4. The embryonic metanephric tissue of claim 4 wherein said growth factor is selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoietins 1 and 2, bone morphogenetic proteins, nerve growth factor, vitamin A, and growth hormone.
5. A method for the treatment of embryonic metanephric tissue comprising contacting embryonic metanephric tissue obtained from a donor at a suitable stage of embryonic development with a growth factor composition comprising a growth factor for metanephric development.
6. The method of claim 5 wherein said growth factor is selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoietins 1 and 2, bone morphogenetic proteins, nerve growth factor, vitamin A, and growth hormone.
7. The method of claim 5 wherein said treatment is *in vivo*.
8. The method of claim 7 wherein said treatment occurs during ureteroureterostomy.
9. The method of claim 5 wherein said treatment is *ex vivo*.
10. The method of claim 9 further comprising the step of transplanting said embryonic metanephric tissue into a recipient.
11. A growth factor composition for enhancing the growth and development of embryonic metanephric tissue comprising two or more growth factors for metanephric development.
12. The growth factor composition of claim 11 wherein said two or more growth factors are selected from the group consisting of insulin-like growth factor I, insulin-like growth factor II, vascular endothelial growth factor, transforming growth factor alpha, transforming growth factor beta, hepatocyte growth factor, fibroblast growth factors, platelet-derived growth factor, leukemia inhibitory factor, angiopoietins 1 and 2, bone morphogenetic proteins, nerve growth factor, vitamin A, and growth hormone.